to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

NCT04593511 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: LY03009 F1
DRUG: LY03009 F2
DRUG: LY03009 F3
DRUG: LY03009 F4

Sponsor

Luye Pharma Group Ltd.